Plastic ampoule of<unk>  Common adverse drug reactions (ADRs) associated with<unk>  therapy include restlessness (akathisia), and focal dystonia. Infrequent ADRs include hypertension, hypotension, hyperprolactinaemia leading to galactorrhea, headache, and extrapyramidal effects such as oculogyric crisis.<unk>  may be the most common cause of drug-induced movement disorders. The risk of extrapyramidal effects is increased in people under 20 years of age, and with high-dose or prolonged therapy. Tardive dyskinesia may be persistent and irreversible in some people. The majority of reports of tardive dyskinesia occur in people who have used<unk>  for more than three months. Consequently, the US Food and Drug Administration (FDA) recommends that<unk>  be used for short-term treatment, preferably less than 12 weeks. In 2009, the FDA required all manufacturers of<unk>  to issue a black box warning regarding the risk of tardive dyskinesia with chronic or high-dose use of the drug. Dystonic reactions may be treated with benzatropine, diphenhydramine, trihexyphenidyl, or procyclidine. Symptoms usually subside with diphenhydramine injected intramuscularly. Agents in the benzodiazepine class of drugs may be helpful, but benefits are usually modest and side effects of sedation and weakness can be problematic. In some cases, the akathisia effects of<unk>  are directly related to the infusion rate when the drug is administered intravenously. Side effects were usually seen in the first 15 min after the dose of<unk> . Rare side effects Diabetes, age, and female gender are risk factors that increase the likelihood of experiencing a neuropsychiatric side effect of<unk> . * Panic disorder * Major depressive disorder * Agoraphobia * Agranulocytosis, supraventricular tachycardia, hyperaldosteronism, neuroleptic malignant syndrome, akathisia and tardive dyskinesia. *<unk> haemoglobinaemia*
Metoclopramide
Omeprazole
Rabeprazole
Lansoprazole
Esomeprazole
Dexlansoprazole
Pantoprazole
Ranitidine